ATUM Extend its Collaboration with Anagram Therapeutics to Develop Enzyme Therapies for Malabsorption and Nutrient Metabolism Disorders
Shots:
- The collaboration combines ATUM’s expertise in enzyme engineering, bioanalytics & ML and Anagram’s expertise in gastrointestinal physiology, enzyme development, and global clinical and scientific thought leader network to advance a pipeline of orally delivered enzymes targeting malabsorption syndromes & nutrient metabolism disorders
- The P-I study has been initiated to evaluate the safety & tolerability of ANG003 for CF-related exocrine pancreatic insufficiency which was conducted through the Cystic Fibrosis Therapeutics Development Network at ~20 national CF care centers in the US
- The study focuses on demonstrating absorption of the byproducts of digestion in plasma using sensitive biomarkers of absorption
Ref: Businesswire | Image: Anagram
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
